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ABSTRACT 
Background: Caffeine has been implicated in energy metabolism regulation in skeletal 
muscle. However, it is unclear whether caffeine affects the regulation of skeletal muscle 
size. In the present study, we evaluated the effect of caffeine on muscle size as well as 
accompanied changes of ubiquitin-proteasome system and Akt/mammalian target of 
rapamycin/p70 s6 kinase (p70S6K) signaling. 
Methods: Differentiated C2C12 myotubes were incubated with caffeine (0, 0.1, 1.0, 3.0 
mM) for 24 h. We then estimated the protein content, myotube diameter, and the 
expression levels of muscle RING finger 1 (MuRF1) mRNA, atrogin-1/muscle atrophy 
F-box (MAFbx) mRNA, K48-linked polyubiquitin, phosphorylated 5′AMP-activated 
protein kinase (AMPK) α Thr172, 72-kDa heat shock protein (HSP72), HSP72 mRNA, 
inhibitor κBα (IκBα), phosphorylated forkhead box class O3a (FoxO3a) Ser253, 
myogenin mRNA, microRNA (miR)-23a, phosphorylated Akt Ser473, and phosphorylated 
p70 s6 kinase (p70S6K) Thr389. 
Results: Protein content and myotube diameter were lower in myotubes treated with 
caffeine (≥1 mM) compared with untreated cells. The expression levels of MuRF1 and 
atrogin-1/MAFbx mRNA and K48-linked polyubiquitin were increased by caffeine 
treatment. However, phosphorylated AMPKα Thr172, HSP72 protein and mRNA, IκBα, 
phosphorylated FoxO3a Ser253, and miR-23a expression were not affected by caffeine 
treatment. Myogenin mRNA expression was upregulated in response to caffeine 
treatment. The expressions of phosphorylated Akt Ser473 and p70S6K Thr389 were 
suppressed by caffeine. 
Conclusions: Caffeine might affect muscle size by stimulating ubiquitin-proteasome 
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INTRODUCTION 
Caffeine is a xanthine alkaloid, which has been implicated in energy metabolism 
regulation in skeletal muscle. Particularly, 5′AMP-activated protein kinase (AMPK) is 
considered to be a crucial mediator of caffeine-mediated metabolic changes in skeletal 
muscle. Several studies have suggested that caffeine (≥1 mM) acutely stimulates AMPK 
in rat skeletal muscle1-8 and that caffeine-stimulated glucose transport is reduced in 
AMPK kinase-dead mice1. Ding et al.9 found that caffeine (1 and 5 mM) treatment for 4 
days (5 h/day) increased mitochondrial biogenesis via an AMPK-dependent mechanism 
in skeletal muscle cells. Furthermore, Mathew et al.10 demonstrated that caffeine (10 mM) 
treatment for 6 h stimulated autophagy in skeletal muscle cells, which was attenuated in 
the presence of an AMPK inhibitor. 
Recently, AMPK has been considered to be a key factor that modulates skeletal 
muscle mass. It was reported that elevated AMPK activity was involved in a diminished 
capacity for hypertrophy in aged rat skeletal muscle11,12 and that overload-induced muscle 
hypertrophy was accelerated in AMPKα1-deficient mice compared with the wild-type 
mice13. Akt/mammalian target of rapamycin (mTOR)/p70 S6 kinase (p70S6K), a central 
signaling modulator of protein synthesis14, is considered to be a potent signaling pathway 
for AMPK-mediated regulation of muscle hypertrophy. On the other hand, in our previous 
study15, we demonstrated that AMPK-associated suppression of muscle hypertrophy in 
skeletal muscle cells was through rather activating protein catabolic pathway than 
inhibiting protein synthesis pathway. 
The ubiquitin-proteasome system is a crucial regulatory mechanism for protein 
catabolism in skeletal muscle. The key enzymes in this pathway are E3 ubiquitin ligases, 
which are responsible for protein ubiquitination. Two muscle-specific ubiquitin ligases, 
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i.e., muscle RING finger 1 (MuRF1) and atrogin-1/muscle atrophy F-box (MAFbx), are 
considered to be involved in skeletal muscle atrophy16,17. Previous studies have 
demonstrated that AMPK activation stimulates protein degradation, which is 
accompanied by the upregulation of MuRF1 and atrogin-1/MAFbx mRNA expression in 
skeletal muscle cells18,19. In accordance with these researches, we15 demonstrated that 
pharmacological AMPK activation altered muscle size through ubiquitin-proteasome 
system and that these responses were not induced in AMPK-knockdown cells in vitro. 
Furthermore, our recent study in vivo20 has shown that the ubiquitin-proteasome system 
was not activated during unloading-induced muscle atrophy in muscle, where the AMPK 
activity decreased. Overall, AMPK-induced activation of ubiquitin-proteasome system 
appears to be involved in the regulation of muscle size. 
Thus, the results of previous studies strongly suggest that caffeine also activates the 
ubiquitin-proteasome system and that it affects the skeletal muscle size through AMPK 
activation. Therefore, in the present study, we aimed to evaluate the effect of caffeine on 
muscle size and accompanied changes of the ubiquitin-proteasome system in skeletal 
muscle cells. In addition, we have previously shown that caffeine inhibited 
Akt/mTOR/p70S6K signaling in rat skeletal muscle7,21, indicating that caffeine may 
inhibit protein synthesis pathway. Therefore, to confirm whether caffeine affects protein 




MATERIALS AND METHODS 
Cell culture and treatment. 
Cell culture was performed as described previously15. Briefly, mouse myoblast 
C2C12 cells were cultured on 6-well culture plates with type I collagen-coated surface 
(Biocoat, Becton-Dickinson Labware, Franklin Lakes, NJ). Cells were maintained in 
growth medium comprising Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, 
Rockville, MD) supplemented with 10% heat-inactivated fetal bovine serum containing 
high glucose (4.5 g/l glucose, 4.0 mM L -glutamine, without sodium pyruvate) to allow 
proliferation under a humidified atmosphere with 95% air and 5% CO2. After reaching 
confluence, the culture medium was replaced with differentiation medium comprising 
DMEM supplemented with 2% heat-inactivated horse serum containing low glucose (1.0 
g/l glucose, 4.0 mM L-glutamine, and 110 mg/l sodium pyruvate) to initiate 
differentiation. The medium was replaced with freshly prepared differentiation medium 
at 2-day intervals over the course of differentiation for 5 days. Five days after the initiation 
of differentiation, myotubes were incubated in differentiation medium containing caffeine 
(Wako, Tokyo, Japan), 5-aminoimidazole-4-carboxamide-1-β-D-ribonucleoside (AICAR, 
Sigma, St. Louis, MO), or metformin (Sigma). To investigate the dose-dependent effects 
of caffeine, the myotubes were incubated in differentiation medium with or without 
caffeine (0, 0.1, 1.0, 3.0 mM) for 24 h. Subsequently, the cells were harvested for western 
blot or real-time RT-PCR analyses. 
 
Myotube diameter measurement. 
Images of myotubes were visualized at 40× magnification using an inverted light 
microscope and captured with a camera (Olympus, Tokyo, Japan). The diameter of 
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myotubes was measured using a modified version of the method described by Williamson 
et al.22. Four fields were chosen randomly and 150 myotubes were measured using ImageJ. 
The average diameter per myotube was calculated as the mean of three short-axis 
measurements taken along the length of the myotube. 
 
Sample preparation. 
Samples were prepared as described previously with some modifications23. Briefly, 
the cells in each well were rinsed twice with ice-cold phosphate-buffered saline. Next, the 
cells were scraped from each well into CelLytic™ M cell lysis reagent (Sigma) with 1% 
(v/v) protease inhibitor cocktail (Sigma) and 1% (v/v) phosphatase inhibitor cocktail 
(Calbiochem, San Diego, CA). The cell lysate was sonicated and centrifuged for 15 min 
at 15,000 × g and 4°C. The supernatant was collected to determine the protein content 
using the Bradford technique (protein assay kit; Bio-Rad, Hercules, CA). The protein 
contents of the supernatant were expressed as mg/ml. 
 
Western blot analyses. 
Western blot analyses were performed as described previously7,23. Extracted samples 
in cell lysis reagents were solubilized in Laemmli’s sample buffer and boiled for 5 min. 
The samples (10 µg of protein) were separated by SDS-PAGE using 10% polyacrylamide 
gel at a constant current of 35 mA/gel for 90 min. Bio-Rad Precision Markers (Bio-Rad 
Laboratories, Hercules, CA) were applied to both sides of the gel as internal controls for 
the transfer process or electrophoresis. 
After SDS-PAGE, the proteins were transferred to polyvinylidene fluoride 
membranes (Hybond-P, GE Healthcare, Buckinghamshire, UK) using trans-blot cell (Bio-
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Rad) at a constant voltage of 100 V for 1 h at 4°C. Next, the membranes were blocked for 
1 h using Blocking One-P (Nacalai Tesque, Kyoto, Japan) or ECL blocking reagent 
(RPN418, GE Healthcare). The membranes were then incubated overnight at 4°C with 
primary antibodies: Akt Ser473 (9271, Cell Signaling Technology, Danvers, MA), Akt 
(9272, Cell Signaling Technology), AMPKα Thr172 (2531, Cell Signaling Technology), 
AMPKα (2532, Cell Signaling Technology), forkhead-box class O (FoxO) 3a Ser253 
(9466, Cell Signaling Technology), FoxO3a (2497, Cell Signaling Technology), 72-kDa 
heat shock protein (HSP72, ADI-SPA-812, Enzo Life Sciences, Farmingdale, NY), 
inhibitor of κBα (IκBα, 9242, Cell Signaling Technology), K48-linkage specific 
polyubiquitin (4298, Cell Signaling Technology), p70S6K Thr389 (9206, Cell Signaling 
Technology), p70S6K (9202, Cell Signaling Technology), and β-actin (4967, Cell 
Signaling Technology). The membranes were washed with Tris-buffered saline 
containing 0.1% Tween 20 (TBS-T, pH 7.5) and reacted with anti-rabbit IgG (Cell 
Signaling Technology) for 1 h at room temperature. After a final wash with TBS-T, the 
protein bands were visualized using chemiluminescence (Wako). The signal density was 
measured using a Light-Capture system (AE-6971, ATTO Corporation, Tokyo, Japan). 
 
Real-time RT-PCR analyses. 
Real-time RT-PCR analyses were performed as described previously24. Briefly, total 
RNA was extracted from muscles using a miRNeasy Mini kit (Qiagen, Hiden, Germany) 
according to the manufacturer’s protocol. To detect MuRF1 (Trim63) mRNA, atrogin-
1/MAFbx (Fbxo32) mRNA, and HSP72 (Hspa1a) mRNA, the RNA was reverse-
transcribed to cDNA using PrimeScript RT Master Mix (Takara Bio), and the synthesized 
cDNA was then subjected to real-time RT-PCR (Thermal Cycler Dice Real Time System 
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IIMRQ, Takara Bio) using Takara SYBR Premix Ex Taq II (Takara Bio). To detect 
microRNA (miR)-23a, the RNA was reverse-transcribed to cDNA using a Mir-XTM 
miRNA First Strand Synthesis Kit (Clontech Laboratories, Mountain View, CA), and the 
synthesized cDNA was then subjected to real-time RT-PCR using a Mir-XTM miRNA 
qRT-PCR SYBR Kit (Clontech Laboratories). Relative fold changes in the expression 
levels were calculated by the comparative CT method using Takara Thermal Cycler Dice 
Real Time System Software Ver. 4.00. To normalize the total amount of RNA present in 
each reaction, 18S ribosomal RNA was used as an internal standard for MuRF1 and 
HSP72, and U6 for miR-23a. 
The following primers were used: Trim63 (MuRF1), 5′-
AGGACTCCTGCAGAGTGACCAA-3′ (forward) and 5′-
TTCTCGTCCAGGATGGCGTA-3′ (reverse); atrogin-1/MAFbx (Fbxo32), 5′-
TGTCCTTGAATTCAGCAAGCAAAC-3′ (forward) and 5′-
TGTGGCCATCCATTATTTCCAG-3′ (reverse); Hspa1a (HSP72), 5′-
CAAGAACGCGCTCGAATCCTA-3′ (forward) and 5′-
TCCTGGCACTTGTCCAGCAC-3′ (reverse); 18S ribosomal RNA, 5′-
ACTCCAAAGGGCACAACTCA-3′ (forward) and 5′-
CCTTTAGGGACCGTTACACTA-3′ (reverse); and miR-23a, 5′-
ATCACATTGCCAGGGATTTCC-3′ (forward). The U6 primer and reverse primers for 
miRNA were provided with the kit. 
 
Statistical analyses. 
All values were expressed as means ± SEM. Differences between two groups were 
compared using the Student’s t-test. Multiple means were analyzed using Dunnett’s 
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multiple comparisons test. Differences in the myotube diameter distributions were 
analyzed using the Chi-squared test. Differences between groups were considered 
statistically significant at P < 0.05. All of the statistical analyses were performed using 




Caffeine inhibited myotube hypertrophy. 
To determine whether caffeine affects myotube size, we measured the protein content 
and myotube diameter in caffeine-treated cells. The dose-response analysis demonstrated 
that the protein content was decreased by caffeine treatment at 1.0 and 3.0 mM compared 
with no treatment (Figure 1A). Correspondingly, the myotube diameter was smaller in 
myotubes treated with caffeine (1 mM) compared with no treatment (Figure 1B). Greater 
numbers of smaller and lower numbers of larger myotubes were observed following 
caffeine treatment (Chi-square test: P < 0.05, Figure 1C). 
 
Caffeine activated the ubiquitin-proteasome system. 
To identify whether caffeine activates the ubiquitin-proteasome system, we analyzed 
the expression levels of MuRF1 and atrogin-1/MAFbx mRNA and K48-linked 
polyubiquitin in myotubes treated with or without caffeine (1 mM). The expression levels 
of MuRF1 mRNA (Figure 2A), atrogin-1/MAFbx mRNA (Figure 2B) and K48-linked 
polyubiquitin (Figure 2C) were increased by caffeine treatment. 
 
Caffeine did not affect AMPK activity or HSP72 expression. 
In a previous study15, we showed that the AMPK-induced suppression of hypertrophy 
is partly mediated by the downregulation of HSP72 protein. Therefore, we investigated 
whether caffeine affects the phosphorylation of AMPKα Thr172, which is the primary site 
responsible for AMPK activation25, and the expression levels of HSP72 protein and 
mRNA. The expression level of phosphorylated AMPKα Thr172 increased (Figure 3A) 
whereas the expression levels of HSP72 protein (Figure 3B) and mRNA (Figure 3C) 
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decreased after treatment with the pharmacological AMPK activators AICAR (0.5 mM) 
and metformin (2 mM). However, there were no changes in AMPKα Thr172 
phosphorylation and the expression levels of HSP72 protein and mRNA under caffeine 
treatment (Figure 3). 
 
Caffeine increased myogenin mRNA expression but not the expression levels of IκBα, 
phosphorylated FoxO3a Ser253, and miR-23a. 
Next, we examined the effects of caffeine on the expression levels of molecules that 
directly or indirectly target MuRF1 and atrogin-1/MAFbx transcriptions. The expression 
levels of IκBα (Figure 4A), phosphorylated FoxO3a Ser253, a key regulatory site for the 
transcription activity26 (Figure 4B), and miR-23a (Figure 4C) were not altered by caffeine 
treatment. By contrast, myogenin mRNA expression was upregulated by caffeine (Figure 
4D). 
 
Caffeine inhibited the protein synthesis pathway. 
To confirm whether caffeine affects the protein synthesis pathway, we evaluated the 
expression levels of phosphorylated Akt Ser473 and p70S6K Thr389, which are the primary 
site responsible for activations of Akt27 and p70S6K28, respectively, in myotubes treated 
with or without caffeine (1 mM). Treatment with caffeine decreased phosphorylation of 




In the present study, we obtained the following novel findings related to the effects 
of caffeine on the regulation of skeletal muscle size. First, caffeine (≥1 mM)-treated 
myotubes had a lower protein content and smaller myotube diameter compared with 
untreated myotubes (Figure 1). Second, caffeine treatment increased the expression levels 
of MuRF1 and atrogin-1/MAFbx mRNA and K48-linked polyubiquitin (Figure 2). Third, 
treatment with AICAR and metformin increased the phosphorylation of AMPKα Thr172 
but decreased the expression levels of HSP72 protein and mRNA. Conversely, caffeine 
treatment had no effects on the phosphorylation of AMPKα Thr172 and the expression 
levels of HSP72 protein and mRNA (Figure 3). Fourth, caffeine treatment increased 
myogenin mRNA expression but not the phosphorylation of FoxO3a Ser253, IκBα, and 
miR-23a (Figure 4). 
A recent study demonstrated that caffeine promotes autophagy in skeletal muscle 
cells10. Autophagy is a crucial cell proteolytic system, which controls protein turnover in 
skeletal muscle29. In the present study, we found that caffeine increased the expression 
levels of MuRF1 and atrogin-1/MAFbx mRNA and K48-linked polyubiquitin (Figure 2), 
suggesting that caffeine also activates another proteolysis pathway, the ubiquitin-
proteasome system. K48-linked polyubiquitination is the best-studied type of poly-
ubiquitination, which typically targets proteins for proteasomal degradation30, and it is 
synthesized by MuRF131 and/or atrogin-1/MAFbx32. Several signaling molecules are 
involved in the regulation of MuRF1 and atogin-1/MAFbx transcriptions. 
AMPK stimulates myofibrillar protein degradation via the upregulation of MuRF1 
and atrogin-1/MAFbx18,19. We hypothesized that caffeine may increase MuRF1 and 
atrogin-1/MAFbx expressions via an AMPK-dependent mechanism since caffeine is 
 15 
known to be a potent activator of AMPK. However, caffeine did not affect the 
phosphorylation of AMPKα Thr172 (Figure 3A). A previous study found that caffeine 
acutely (approximately 4 h) increased the phosphorylation of AMPKα Thr172, but it 
returned to the control level by 12 h in skeletal muscle cells33. Our results support these 
findings, and it is suggested that AMPK signaling was transiently activated following 
caffeine treatment but returned to the basal state at 24 h in the present study.  
The AMPK-mediated activation of the ubiquitin-proteasome system is partly 
dependent on HSP72. In a previous study15, we demonstrated that the AMPK-mediated 
upregulation of MuRF1 mRNA is suppressed in HSP72-knockdown cells. HSP72 is one 
of the most prominent members of the HSP family, and it is considered to have an 
important role in controlling skeletal muscle mass34,35. HSP72 targets FoxOs, a 
transcriptional factor of MuRF136. In the present study, there were no changes in the 
expression levels of HSP72 protein and mRNA (Figure 3), or in the phosphorylation of 
FoxO3a Ser253 (Figure 4B). Overall, in contrast to our expectations, our results suggest 
that caffeine upregulates the ubiquitin-proteasome system via an AMPK-independent 
mechanism. However, it cannot be excluded the possibility that the transient activation of 
AMPK might affect the caffeine-mediated responses in the present study. In this regard, 
further investigations, using a pharmacological blocker or cells with knockdown of 
AMPK, are necessary to understand the role of AMPK in caffeine-mediated regulation of 
muscle size. 
NF-κB, miR-23a, and myogenin are potent molecules that transcribe MuRF1 and/or 
atrogin-1/MAFbx. NF-κB is a transcriptional factor, which is sequestered in the 
cytoplasm by a family of inhibitory proteins called IκBα37. The IκB kinase complex 
phosphorylates IκBα, thereby resulting in its degradation, which leads to the nuclear 
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translocation of NF-κB and its activation. It has been reported that NF-κB sites are 
required for the transcriptional activation of MuRF1 during the regulation of muscle 
mass38. However, in the present study, we found that IκBα expression was not affected 
by caffeine (Figure 4B). 
miRs comprise a novel class of small, non-coding endogenous RNAs, which regulate 
gene expression by directing their target mRNAs for degradation or translational 
repression39,40. Recently, it was shown that miR-23a suppresses post-transcriptional 
MuRF1 and atrogin-1/MAFbx expressions in vitro and that the forced expression of miR-
23a in skeletal muscle leads to resistance against atrophy by regulating MuRF1 and 
atrogin-1/MAFbx genes41. In the present study, caffeine did not affect the expression level 
of miR-23a (Figure 4C). 
Myogenin is an essential transcription factor for skeletal muscle development42, 
which binds and activates the promoter regions of the MuRF1 and atrogin-1/MAFbx 
genes43. It has been demonstrated that the upregulation of MuRF1 and atrogin-1/MAFbx 
in denervated skeletal muscle was impaired in myogenin null mice43. In the present study, 
caffeine upregulated the expression level of myogenin mRNA (Figure 4D), which 
suggests that caffeine might activate the ubiquitin-proteasome system by increasing 
myogenin-mediated MuRF1 and atrogin-1/MAFbx transcriptions. 
Skeletal muscle mass is regulated by the rate of protein turnover, namely the balance 
between protein synthesis and degradation44. In previous studies7,21, we showed that 
caffeine treatment acutely inhibits the Akt/mTOR/p70S6K signaling in rat skeletal 
muscle. Correspondingly, in the present study, we confirmed that caffeine decreased 
phosphorylation of Akt Ser473 (Figure 5A) as well as p70S6K Thr389 (Figure 5B) in 
caffeine-treated cells, suggesting that caffeine also affects protein synthesis pathway in 
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addition to proteolysis pathway. Taken together, the data obtained the present study 
suggests that the decreased muscle size (Figure 1) by caffeine might be attributed to the 
disturbance of protein turnover, including suppression of protein synthesis and 
stimulating protein degradation. 
In terms of exercise, caffeine ingestion elicits high performance with respect to the 
endurance capacity and muscle strength45. However, caffeine might also inhibit protein 
synthesis and stimulate protein degradation, given that caffeine suppresses the 
Akt/mTOR/p70S6K signaling pathway as well as promoting the autophagy10 and 
ubiquitin-proteasome pathways. Therefore, caffeine ingestion may possibly affect muscle 
size: inhibiting muscle hypertrophy or promoting muscle atrophy. Furthermore, it has 
been shown that caffeine ingestion acutely lowers glucose tolerance in skeletal muscle46 
by preventing insulin signal transduction7. Therefore, caffeine is not necessarily 
beneficial for muscle functions. To the best of our knowledge, the present study is the 
first to demonstrate the involvement of caffeine in the regulation of muscle size and the 
ubiquitin-proteasome system in skeletal muscle. Further research should clarify the 
effects of caffeine on skeletal muscle size in physiological conditions to obtain a better 




In this study, we showed that caffeine treatment reduced in myotube size in cultured 
C2C12 cells and stimulated the ubiquitin-proteasome system. In addition, caffeine 
treatment did not promote AMPK signaling or its associated molecules, whereas it 
upregulated myogenin mRNA expression. On the other hand, the protein synthesis 
pathway was inhibited by caffeine. The results obtained in the present study indicate that 
caffeine might affect muscle size by stimulating ubiquitin-proteasome system and 
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Effects of caffeine on the: (A) protein content, (B) myotube diameter, and (C) C2C12 
myotube diameter distribution. Myotubes were incubated in differentiation medium 
without or with caffeine (A: indicated concentration; B and C: 1 mM) for 24 h. 
Representative images of myotubes are also shown. Scale bars indicate 100 μm. Values 
represent the mean ± SEM. n = 6 per group. *: P < 0.05 vs. no treatment. 
 
Figure 2 
Effects of caffeine on the expression levels of: (A) MuRF1 mRNA, (B) atrogin-
1/MAFbx mRNA and (C) K48-linked polyubiquitin (K48-Ub) in C2C12 myotubes. 
Myotubes were incubated in differentiation medium without or with caffeine (1 mM) for 
24 h. Representative immunoblots are also shown. Values represent the mean ± SEM. n 
= 3-6 per group. *: P < 0.05 vs. no treatment. 
 
Figure 3 
Effects of caffeine, AICAR, or metformin on the expression levels of: (A) 
phosphorylated AMPK Thr172 (p-AMPK)/AMPK, (B) HSP72, and (C) HSP72 mRNA in 
C2C12 myotubes. Myotubes were incubated in differentiation medium without or with 
caffeine (1 mM), AICAR (0.5 mM), and metformin (2 mM) for 24 h. Representative 
immunoblots are also shown. Values represent the mean ± SEM. n = 6 per group. *: P < 




Effects of caffeine on the expression levels of: (A) IκBα, (B) phosphorylated FoxO3a 
Ser253 (p-FoxO3a)/FoxO3a, (C) miR-23a, and (D) myogenin mRNA in C2C12 myotubes. 
Myotubes were incubated in differentiation medium without or with caffeine (1 mM) for 
24 h. Representative immunoblots are also shown. Values represent the mean ± SEM. n 
= 6 per group. *: P < 0.05 vs. no treatment. 
 
Figure 5 
Effects of caffeine on the expression levels of: (A) phosphorylated Akt Ser473 (p-
Akt)/Akt and (B) phosphorylated p70S6K Thr389 (p-p70S6K)/p70S6K in C2C12 
myotubes. Myotubes were incubated in differentiation medium without or with caffeine 
(1 mM) for 24 h. Representative immunoblots are also shown. Values represent the mean 
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